FDA approves Nemluvio for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.
The Healthy on MSN5d
12 Silent Signs of Skin Cancer You’re Probably Ignoring
Dermatologists recommend that you do a monthly self-check of your moles and any other skin abnormalities to help catch ...
Medscape1mon
Gender Difference in Vesiculobullous Autoimmune Skin Diseases
[25] Anti-BP Antigen Mucosal Pemphigoid. These patients have a mucosal disease with skin lesions and show IgG circulating antibodies directed against BP antigens. Oral Pemphigoid. Oral pemphigoid ...
Medscape1mon
What's Your Assessment?
The primary skin lesions are erythematous plaques with violaceous ... Eosinophilic cellulitis or Bullous pemphigoid are the remaining options. Bullous pemphigoid should always be in the ...